An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks

被引：0
|
作者：
Julia Ramírez-Moya
Christos Miliotis
Allison R. Baker
Richard I. Gregory
Frank J. Slack
Pilar Santisteban
机构：
[1] Universidad Autónoma de Madrid (UAM),Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC)
[2] Harvard Medical School,Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center
[3] Harvard Medical School Initiative for RNA Medicine,Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School
[4] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII),undefined
来源：
Molecular Cancer | / 20卷
关键词：
ADAR1; A-to-I editing; Cancer; CDK13; Splicing;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks
    Ramirez-Moya, Julia
    Miliotis, Christos
    Baker, Allison R.
    Gregory, Richard, I
    Slack, Frank J.
    Santisteban, Pilar
    MOLECULAR CANCER, 2021, 20 (01)
  • [2] ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
    Zhu, Tianyu
    Li, Qian
    Zhang, Zhe
    Shi, Jiahao
    Li, Yongyun
    Zhang, Feng
    Li, Lingjie
    Song, Xin
    Shen, Jianfeng
    Jia, Renbing
    BMC BIOLOGY, 2024, 22 (01)
  • [3] ADAR1-Dependent RNA Editing Promotes MET and iPSC Reprogramming by Alleviating ER Stress
    Guallar, Diana
    Fuentes-Iglesias, Alejandro
    Souto, Yara
    Ameneiro, Cristina
    Freire-Agulleiro, Oscar
    Angel Pardavila, Jose
    Escudero, Adriana
    Garcia-Outeiral, Vera
    Moreira, Tiago
    Saenz, Carmen
    Xiong, Heng
    Liu, Dongbing
    Xiao, Shidi
    Hou, Yong
    Wu, Kui
    Torrecilla, Daniel
    Hartner, Jochen C.
    Blanco, Miguel G.
    Lee, Leo J.
    Lopez, Miguel
    Walkley, Carl R.
    Wang, Jianlong
    Fidalgo, Miguel
    CELL STEM CELL, 2020, 27 (02) : 300 - +
  • [4] Targets of the cyclin-dependent kinase Cdk1
    Jeffrey A. Ubersax
    Erika L. Woodbury
    Phuong N. Quang
    Maria Paraz
    Justin D. Blethrow
    Kavita Shah
    Kevan M. Shokat
    David O. Morgan
    Nature, 2003, 425 : 859 - 864
  • [5] Targets of the cyclin-dependent kinase Cdk1
    Ubersax, JA
    Woodbury, EL
    Quang, PN
    Paraz, M
    Blethrow, JD
    Shah, K
    Shokat, KM
    Morgan, DO
    NATURE, 2003, 425 (6960) : 859 - 864
  • [6] Reduced Endothelial ADAR1-Dependent RNA Editing Induces NOCT-Driven Immunoactivation and Promotes Pulmonary Hypertension
    Woodcock, Chen-Shan J.
    Maroli, Giovanni
    Kim, Hyunbum
    Tang, Ying
    Tai, Yi Yin
    Okawa, Satoshi
    Cho, Shu-Ting
    Lafyatis, Robert
    Chauvet, Caroline
    Kudryashova, Tatiana
    Goncharova, Elena A.
    Bertero, Thomas
    Yuan, Ke
    Pullamsetti, Soni
    Chan, Stephen Y.
    CIRCULATION, 2023, 148
  • [7] Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing
    Liang, Kaiwei
    Gao, Xin
    Gilmore, Joshua M.
    Florens, Laurence
    Washburn, Michael P.
    Smith, Edwin
    Shilatifard, Ali
    MOLECULAR AND CELLULAR BIOLOGY, 2015, 35 (06) : 928 - 938
  • [8] ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies
    Lazzari, Elisa
    Crews, Leslie A.
    Wu, Christina
    Leu, Heather
    Ali, Shawn
    Chiaramonte, Raffaella
    Minden, Mark
    Costello, Caitlin
    Jamieson, Catriona H. M.
    CANCER RESEARCH, 2016, 76
  • [9] Regulation of telomere elongation by the cyclin-dependent kinase CDK1
    Frank, Christopher J.
    Hyde, Molly
    Greider, Carol W.
    MOLECULAR CELL, 2006, 24 (03) : 423 - 432
  • [10] An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
    Liu, Xuanyou
    Wu, Hao
    Liu, Zhenguo
    CANCERS, 2022, 14 (11)
12345